|
Match
|
Document |
Document Title |
|
|
6207171 |
Polyphosphazene microspheres
A soluble polyphosphazene polyelectrolyte immunoadjuvant is disclosed. In one embodiment, the polymeric adjuvant is poly[di(carboxylatrophenoxy)phosphazene] which is in the form of a microsphere...
|
|
|
6149922 |
Vaccine adjuvant and vaccine
The present invention includes novel polyoxyethylene/polyoxypropylene block copolymers as well as methods for making the block copolymers. The block copolymers are high molecular weight molecules...
|
|
|
6149911 |
Method for enhancing the immunogenicity of an immunogenic compound or hapten, and use thereof for preparing vaccines
The present invention relates to a process for improving the immunogenicity of an immunogen, an antigen or a hapten, when it is administered to a host, independently of the mode of administration,...
|
|
|
6139862 |
Pharmaceutical dipeptide compositions and methods of use thereof
Methods are provided for the therapy of immunodeficient, immunodepressed or hyperactive immune states and for the prevention and treatment of opportunistic infections in such states comprising...
|
|
|
6113902 |
Immunogenic compositions comprising peptides from β-2-microglobulin
An immunogenic composition for treating and/or preventing infectious diseases where the infectious agent has at least one intracellular phase in the host during its multiplication cycle, is...
|
|
|
6093699 |
Method for gene therapy involving suppression of an immune response
A method for specifically suppressing the capacity of a mammal receiving gene therapy to mount an immune response to a given expressed gene of the deficient gene in question, which response is...
|
|
|
6017537 |
Formyl methionyl peptide vaccine adjuvant
The present invention relates to immunological adjuvants comprised of the N-formyl methionyl peptide fMLP. FMLP, when used as an adjuvant in accordance with the present invention, provides for an...
|
|
|
6015563 |
Polyphosphazene polyelectrolyte immunoadjuvants
A polyphosphazene polyelectrolyte immunoadjuvant having improved water solubility, a vaccine composition of the immunoadjuvant and an antigen or immunogen and methods of their use in producing or...
|
|
|
5998588 |
Interactive molecular conjugates
The combination of the capabilities of stimuli-responsive components such as polymers and interactive molecules to form site-specific conjugates which are useful in a variety of assays,...
|
|
|
5958414 |
Composition to protect a mammal against Bartonella henselae infection
The present invention relates to a therapeutic composition to protect a mammal from B. henselae infection that includes an isolated B. henselae antigen and an adjuvant comprising a phosphazene...
|
|
|
5955079 |
Dual carrier immunogenic construct
A dual carrier immunogenic construct comprised of at least one primary carrier comprising large molecular weight molecule of greater than a 70 KD molecular weight and at least one secondary carrier...
|
|
|
5942237 |
Pharmaceutical preparation for topical administration of antigens and/or vaccines to mammals via a mucosal membrane
A novel type of formulation for the topical administration of antigens and/or vaccines to mammals via mucosal membranes comprising one or more adjuvants/vehicles selected from (a) polyoxyethylene...
|
|
|
5919442 |
Hyper comb-branched polymer conjugates
A novel class of hyper comb-branched polymers conjugated with carried materials are disclosed.
|
|
|
5891444 |
HIV-1 prophylactic composition and method
A composition and method for inducing a protective immune response to HIV-1 in an individual, of (a) a replication incompetent HIV-1, HIV-1 pseudovirus, HIV-1 VLP or oligomeric gp120; and (b) a...
|
|
|
5885590 |
Oral vaccines comprising multiple emulsions and methods of preparation
The present invention relates to water-in-oil and water-in-oil-in-water multiple emulsions and methods of preparation which overcome many of the limitations of previous emulsions and are superior...
|
|
|
5858368 |
Vaccine comprising a baculovirus produced influenza hemagglutinin protein fused to a second protein
A method of preparing a recombinant influenza vaccine using DNA technology is provided. The resulting vaccine is a multivalent, preferably trivalent, influenza vaccine based on a mixture of...
|
|
|
5849859 |
Polyesters
A biodegradable and biocompatible polyester comprising (C 3 -10) alkylene carbonic acid ester units, each alkylene group being a C 3 -alkylene group having 1 oxy substituent or a (C 4 -10)...
|
|
|
5844061 |
Polyphenol derivative compositions and perparation thereof
Polyphenol derivative compositions including oligomer or polymer esters containing N+2 monomer moieties, whose monomer moieties correspond to the following formula ##STR1## in which N is a number...
|
|
|
5824322 |
Compositions and methods for growth promotion
The present invention includes compositions and methods using biologically active nonionic reverse block copolymers. The reverse copolymers have an inner core of polyoxypropylene (POP) that is...
|
|
|
5817757 |
Inhibitors of peptide binding to MHO class II proteins
Compounds of the formula ##STR1## are inhibitors of peptide binding to major histocompatibility complex type II proteins and are useful in the treatment and prevention of autoimmune diseases...
|
|
|
5811100 |
Compounds for the prevention and treatment of helmith infections
A compound for protecting a vertebrate against infection by helminths comprising hyaluronidase covalently coupled to an immunostimulating carrier, in preferred form, the immunostimulating carrier...
|
|
|
5785975 |
Adjuvant compositions and vaccine formulations comprising same
The present invention relates to phospholipid-polysaccharide adjuvant compositions and to vaccine formulations comprising same, as well as to methods of making and using such adjuvants and vaccines.
|
|
|
5773522 |
Polymer-bound camptothecin derivatives
A polymeric conjugate consists essentially of: (i) from 60 to 99 mol % of N-(2-hydroxypropyl) methacryloylamide units represented by formula 1: ##STR1## (ii) from 1 to 40 mol % of...
|
|
|
5753234 |
Single-shot vaccine formulation
A microparticle having a particle size ranging from 0.5 to 300 μm, which is prepared by dissolving an antigen or a mixture of antigens in an aqueous solution, adding a water-soluble substance...
|
|
|
5747045 |
Avian polyomavirus vaccine in psittacine birds
The present invention provides a vaccine which is protective against avian polyomavirus infection in a bird which is classified as being a member of the Psittaciformes order which comprises an...
|
|
|
5686071 |
Polymer affinity system for the delivery of cytotoxic material and other compounds to sites of disease
The use of interacting polymers and oligomers to selectively target compounds to desired sites, in-vitro and in-vivo, wherein the first polymer or oligomer is bound to a targeting agent and the...
|
|
|
5683986 |
Elaboration of host defense mediators into biological fluids by systemic dsRNA treatment
Parenterally administered systemic dsRNAs release host mediators into various compartmentalized biological fluids to combat various microorganisms, particularly viruses, thereby reducing the...
|
|
|
5679355 |
Vaccines containing non-ionic surfactant vesicles
Non-ionic surfactant vesicles (NSIV) with entrapped antigen act as potent immunological adjuvants and can produce antibody titers of the same order of magnitude as those using Freund's Complete...
|
|
|
5674495 |
Alginate-based vaccine compositions
A vaccine composition including an antigen dispersed in an alginate gel is described. The alginate gel is preferably in the form of discrete particles coated with a polymer. Vaccination of...
|
|
|
5562909 |
Phosphazene polyelectrolytes as immunoadjuvants
A immunoadjuvant soluble phosphazene polyelectrolyte is disclosed. In one embodiment, the polymeric adjuvant is an poly(organophosphazene) with (i) ionized or ionizable pendant groups that contain,...
|
|
|
5554372 |
Methods and vaccines comprising surface-active copolymers
The present invention comprises adjuvants which, when admixed with an antigen and administered into a human or animal, will induce a more intense immune response to the antigen than when the...
|
|
|
5503830 |
Compounds having immunostimulating activity and methods of use thereof
Polymeric compounds comprising subunits of the following formulas ##STR1## wherein R 1 , X, x, y, z, x', y' and z' are as defined in the application. The polymeric compounds are capable of...
|
|
|
5494673 |
Phosphazene polyelectrolytes as immunoadjuvants
An immunoadjuvant soluble polyphosphazene polyelectrolyte is disclosed. In one embodiment, the polymeric adjuvant is an poly(organophosphazene) with (i) ionized or ionizable pendant groups that...
|
|
|
5494670 |
Method of treating ketosis
In a method of treating ketosis in an animal during pregnancy or lactation, such as toxaemia of pregnancy or fat cow syndrome, the amount or activity of somatotropin in the blood is increased while...
|
|
|
5447722 |
Method for the suppression of an immune response with antigen-MPEG conjugates in nonsensitized individuals
A method for suppressing the capacity of a mammal to mount an immune response which would be caused by the administration of one or more biologically active foreign proteins, comprising the...
|
|
|
5358710 |
Method for the suppression of an immune response
A method for suppressing the capacity of a mammal to mount an immune response which would be caused by the administration of one or more biologically active foreign proteins, comprising the...
|
|
|
5352448 |
Oral administration of antigens
An oral vaccine formulation is provided for stimulation of an immune response in gut-associated lymphoid tissues. The formulation comprises an enzymatically degradable antigen in a hydrogel matrix....
|
|
|
5206014 |
Synthetic nonapeptide for use as an adjuvant
The specification relates to a synthetic peptide converted into a salt comprising one or more amine groups and capable of potentiating in vivo the primary and secondary antibody response to...
|
|
|
5178860 |
Adjuvant complexes and vaccine made therefrom
"Iscom" adjuvant matrices, comprising a sterol, a glycoside, a solubilized water-insoluble antigen and, optionally, a phospholipid, may be formed without removing the solubilizing agent used for...
|
|
|
5100663 |
Tyr-Gly compositions useful in increasing immune response
Compositions for delaying the progression from AIDS to ARC, and for alleviating symptoms of AIDS and ARC are disclosed together with clinical results of use of such compositions in clinical trials...
|
|
|
5075109 |
Method of potentiating an immune response
A method of delivering a bioactive agent to an animal entailing the steps of encapsulating effective amounts of the agent in a biocompatible excipient to form microcapsules having a size ranging...
|
|
|
5047238 |
Adjuvants for vaccines
An efficacious parenterally administered inactivated canine coronavirus vaccine which provides systemic, humoral protection and also protection of the intestinal tract in dogs from infection by...
|
|
|
5032405 |
Oral pharmaceutical composition for acid sensitive proteinaceous agents
An orally administrable formulation of a biologically active, acid sensitive, proteinaceous agent comprises a composition of a lyophilized mixture of the proteinaceous agent and maltose, optionally...
|
|
|
5026546 |
Stabilized adjuvant suspension comprising dimethyl dioctadecyl ammonium bromide
A stabilized aqueous adjuvant suspension of dimethyl dioctadecyl ammonium bromide stabilized with at least 0.1 part by weight of a polymer of acrylic acid crosslinked with polyallyl sucrose per...
|
|
|
5008116 |
Immunostimulatory microsphere
The invention relates to the use of an improved carrier or adjuvant to induce a therapeutic response to a weak antigen.
|
|
|
4975420 |
Agents and procedures for provoking an immune response to GnRH and immuno sterilizing mammals
A technique has been developed to cause a mammal to generate antibodies which will bind to its native GnRH thus suppressing the mammal's fertility. The technique involves vaccinating a mammal with...
|
|
|
4933179 |
Feline leukemia virus antigen vaccines
A vaccine for immunizing animals against Feline Leukemia Virus (FeLV) infections contains an FeLV antigen emulsified with a polyoxypropylene-polyoxyethylene block polymer, a glycol ether-based...
|
|
|
4902500 |
Stabilization of antibodies
According to the present invention antibody preparations are more stable during storage if in addition they contain a mixture of at least one polyoxypropylene-polyoxyethylene block polymer (such as...
|
|
|
4863735 |
Biodegradable polymeric drug delivery system with adjuvant activity
An antigen delivery system utilizing a biodegradable polymer with good mechanical properties in combination with a material stimulating the immune system. The material having adjuvant activity may...
|
|
|
4857318 |
Bordetella bronchiseptica pilus subunit protein vaccine effective against bordetella pertussis
A vaccine derived from Bordetalla bronchiseptica effective against Bordetella pertussis infection is disclosed herein.
|